» Articles » PMID: 26430964

Overexpression of Bcl-2 Induces STAT-3 Activation Via an Increase in Mitochondrial Superoxide

Overview
Journal Oncotarget
Specialty Oncology
Date 2015 Oct 3
PMID 26430964
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

We recently reported a novel interaction between Bcl-2 and Rac1 and linked that to the ability of Bcl-2 to induce a pro-oxidant state in cancer cells. To gain further insight into the functional relevance of this interaction, we utilized computer simulation based on the protein pathway dynamic network created by Cellworks Group Inc. STAT3 was identified among targets that positively correlated with Rac1 and/or Bcl-2 expression levels. Validating this, the activation level of STAT3, as marked by p-Tyr705, particularly in the mitochondria, was significantly higher in Bcl-2-overexpressing cancer cells. Bcl-2-induced STAT3 activation was a function of GTP-loaded Rac1 and NADPH oxidase (Nox)-dependent increase in intracellular superoxide (O2•-). Furthermore, ABT199, a BH-3 specific inhibitor of Bcl-2, as well as silencing of Bcl-2 blocked STAT3 phosphorylation. Interestingly, while inhibiting intracellular O2•- blocked STAT3 phosphorylation, transient overexpression of wild type STAT3 resulted in a significant increase in mitochondrial O2•- production, which was rescued by the functional mutants of STAT3 (Y705F). Notably, a strong correlation between the expression and/or phosphorylation of STAT3 and Bcl-2 was observed in primary tissues derived from patients with different sub-sets of B cell lymphoma. These data demonstrate the presence of a functional crosstalk between Bcl-2, Rac1 and activated STAT3 in promoting a permissive redox milieu for cell survival. Results also highlight the potential utility of a signature involving Bcl-2 overexpression, Rac1 activation and STAT3 phosphorylation for stratifying clinical lymphomas based on disease severity and chemoresistance.

Citing Articles

The Estrogen-Autophagy Axis: Insights into Cytoprotection and Therapeutic Potential in Cancer and Infection.

Zhao Y, Klionsky D, Wang X, Huang Q, Deng Z, Xiang J Int J Mol Sci. 2024; 25(23).

PMID: 39684286 PMC: 11641569. DOI: 10.3390/ijms252312576.


STAT3 Regulates the Redox Profile in MDA-MB-231 Breast Cancer Cells.

Rodrigues J, Pires B, de Amorim I, Siqueira P, de Sousa Rodrigues M, da Fonseca A Cell Biochem Biophys. 2024; 82(4):3507-3516.

PMID: 39033092 DOI: 10.1007/s12013-024-01439-x.


WDR12/RAC1 axis promoted proliferation and anti-apoptosis in colorectal cancer cells.

Wen S, Huang X, Xiong L, Zeng H, Wu S, An K Mol Cell Biochem. 2024; 479(12):3341-3354.

PMID: 38341833 DOI: 10.1007/s11010-024-04937-x.


Molecular and Therapeutic Insights of Alpha-Lipoic Acid as a Potential Molecule for Disease Prevention.

Tripathi A, Ray A, Mishra S, Mall Bishen S, Mishra H, Khurana A Rev Bras Farmacogn. 2023; 33(2):272-287.

PMID: 36778891 PMC: 9904877. DOI: 10.1007/s43450-023-00370-1.


Targeting Mitochondrial-Derived Reactive Oxygen Species in T Cell-Mediated Autoimmune Diseases.

Chavez M, Tse H Front Immunol. 2021; 12:703972.

PMID: 34276700 PMC: 8281042. DOI: 10.3389/fimmu.2021.703972.


References
1.
Barve A, Gupta A, Solapure S, Kumar A, Ramachandran V, Seshadri K . A kinetic platform for in silico modeling of the metabolic dynamics in Escherichia coli. Adv Appl Bioinform Chem. 2011; 3:97-110. PMC: 3170011. DOI: 10.2147/AABC.S14368. View

2.
Wong A, Soo R, Tan D, Lee S, Lim J, Marban P . Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann Oncol. 2015; 26(5):998-1005. DOI: 10.1093/annonc/mdv026. View

3.
Song H, Wang R, Wang S, Lin J . A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci U S A. 2005; 102(13):4700-5. PMC: 555708. DOI: 10.1073/pnas.0409894102. View

4.
Frank D . STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 2006; 251(2):199-210. DOI: 10.1016/j.canlet.2006.10.017. View

5.
Johnston P, Grandis J . STAT3 signaling: anticancer strategies and challenges. Mol Interv. 2011; 11(1):18-26. PMC: 3063716. DOI: 10.1124/mi.11.1.4. View